Alchemab Therapeutics
23 Nov, 2024
Co-founder Jane Osbourn recently succeeded Young Kwon as CEO of the company which studies the unique antibody response of resilient individuals to develop drugs based on naturally derived antibodies to prevalent, hard-to-treat diseases which do not have disease modifying therapies.
Alchemab has already raised more than $80m from a blue chip syndicate of specialist backers. In June, it was awarded a grant of $595k by The Michael J. Fox Foundation for Parkinson’s Research to support its Parkinson’s disease programme.